癌栓粘连血管壁对非转移性肾细胞癌合并下腔静脉癌栓患者手术及预后的影响

doi:10.19723/j.issn.1671-167X.2021.04.007

摘要/Abstract

摘要：

目的: 评估癌栓粘连静脉壁对肾细胞癌伴下腔静脉癌栓患者手术难度和预后的影响。方法: 对北京大学第三医院泌尿外科于2017年1月至2020年6月收治的94例非转移性肾细胞癌合并下腔静脉癌栓患者进行回顾性队列研究,收集患者的一般情况、临床病理特征、手术及生存信息。按术中发现癌栓粘连静脉壁为标准将患者分为两组,其中64例为癌栓粘连静脉壁组(deep invasive tumor thrombus, DITT), 30例为非粘连组(non-invasive tumor thrombus, NITT)。分别采用卡方检验、t检验和Mann-Whitney U检验进行两组间分类变量和连续变量的单因素比较,绘制Kaplan-Meier曲线并进行多变量Cox回归分析以评估癌栓粘连静脉壁对患者预后的影响。结果: 与NITT组相比,DITT组患者的手术难度明显增加,主要表现为手术时间更长(362.5 vs. 307.5 min,P=0.010),手术出血量更多(1 200 vs. 450 mL,P=0.006),围术期输血量更多(800 vs. 0 mL,P=0.021),血浆输注量更多(200 vs. 0 mL,P=0.001),开放手术占比更高(70.3% vs. 36.7%,P=0.002),术后住院时间更长(9.5 vs. 8.0 d,P=0.036),且发生术后并发症的比例更高(46.9% vs. 13.8%,P=0.002)。DITT与患者的总生存期更差呈正相关(P=0.022),即使在多因素分析中,DITT仍是影响肾细胞癌伴下腔静脉癌栓患者术后总生存率的不良预后因素[HR: 4.635 (1.017~21.116),P=0.047]。结论: 对于非转移性肾细胞癌合并下腔静脉癌栓的患者而言,癌栓粘连静脉壁会明显增加其手术难度,并与患者的不良预后相关。

关键词: 肾细胞癌, 下腔静脉, 癌栓, 预后

Abstract:

Objective: To evaluate the impact of deep invasive tumor thrombus on the surgical complexity and prognosis of patients with renal cell carcinoma complicated with inferior vena cava tumor thrombus. Methods: We retrospectively reviewed the clinical data of 94 patients with non-metastatic renal cell carcinoma complicated with inferior vena cava tumor thrombus, who underwent surgical treatment in Peking University Third Hospital from January 2017 to June 2020. The patient’s general condition, clinicopathological characteristics, surgery and survival information were collected. The patients were divided into two groups based on the intra-operative findings of tumor thrombus adhesion to the venous wall, of which 64 cases were in the deep invasive tumor thrombus (DITT) group and 30 cases were in the non-invasive tumor thrombus (NITT) group. Chi-square, t test and Mann-Whitney U test were used for categorical and continuous variables respectively. Kaplan-Meier plots and multivariable Cox regressions were performed to evaluate the influence of DITT on the prognosis of the patients with renal cell carcinoma with inferior vena cava tumor thrombus. Results: DITT significantly increase the difficulty of surgery for the patients with renal cell carcinoma with venous tumor thrombus, which was mainly reflected in the longer operation time (362.5 vs. 307.5 min, P=0.010), more surgical bleeding (1 200 vs. 450 mL, P=0.006), more surgical blood transfusion (800 vs. 0 mL, P=0.021), more plasma transfusion (200 vs. 0 mL, P=0.001), a higher proportion of open surgery (70.3% vs. 36.7%, P=0.002), a longer post-operative hospital stay (9.5 vs. 8 days, P=0.036), and a higher proportion of post-operative complications (46.9% vs. 13.8%, P=0.002). DITT was associated with worse overall survival of the patients with renal cell carcinoma with inferior vena cava tumor thrombus (P=0.022). Even in the multivariate analysis, DITT was still a poor prognostic factor for the overall survival of these patients [HR: 4.635 (1.017-21.116), P=0.047]. Conclusion: For patients with non-metastatic renal cell carcinoma with inferior vena cava tumor thrombus, DITT will significantly increase the difficulty of surgery, and may lead to poor prognosis.

Key words: Renal cell carcinoma, Inferior vena cava, Tumor thrombus, Prognosis

中图分类号:

R737.11

赵勋,颜野,黄晓娟,董靖晗,刘茁,张洪宪,刘承,马潞林. 癌栓粘连血管壁对非转移性肾细胞癌合并下腔静脉癌栓患者手术及预后的影响[J]. 北京大学学报（医学版）, 2021, 53(4): 665-670.

ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus[J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.

图/表 5

图1

表1

DITT组和NITT组临床和病理特征比较"

Items	DITT (n=64)	NITT (n=30)	t/U/χ²	P value
Age/years	60.4±8.9	59.4±10.9	0.453	0.652
Gender			3.548	0.060
Male	52 (81.3%)	19 (63.3%)
Female	12 (18.8%)	11 (36.7%)
Side			0.121	0.728
Left	17 (26.6%)	9 (30.0%)
Right	47 (73.4%)	21 (70.0%)
Clinical symptoms			1.294	0.523
No clinical symptoms	13 (20.3%)	7 (23.3%)
Local symptoms	36 (56.3%)	19 (63.3%)
Systemic symptoms	15 (23.4%)	4 (13.3%)
BMI/(kg/m²)	24.7±3.5	24.0±2.8	0.893	0.374
Tumor diameter/cm	8.1±2.9	9.1±2.8	1.684	0.096
Hb/(g/L)	120.3±20.4	130.3±20.7	2.203	0.030
Neu/(×10⁹/L)	4.8±1.7	4.2±1.1	1.784	0.078
Plt/(×10⁹/L)	255.0±118.6	262.7±77.8	0.325	0.746
ALP/(U/L)	91.6±37.6	85.6±22.5	0.802	0.424
Alb/(g/L)	39.1±5.1	40.5±4.4	1.257	0.212
Ca/(mg/L)	2.3±0.2	2.2±0.1	0.552	0.583
SCr/(μmol/L)	100.2±25.3	90.8±20.4	1.766	0.081
SCr after surgery/(μmol/L)	116.5±54.2	101.9±37.7	1.259	0.211
ASA score			5.876	0.053
1	3 (4.7%)	2 (6.7%)
2	50 (78.1%)	28 (93.3%)
3	11 (17.2%)	0 (0)
pN stage			4.099	0.052
N0	56 (87.5%)	30 (100.0%)
N1	8 (12.5%)	0 (0)
Mayo classification			8.755	0.033
Ⅰ	11 (17.2%)	12 (40.0%)
Ⅱ	40 (62.5%)	15 (50.0%)
Ⅲ	8 (12.5%)	0 (0)
Ⅳ	5 (7.8%)	3 (10.0%)
Pathology type			0.424	0.769
Clear cell carcinoma	52 (81.3%)	26 (86.7%)
Non clear cell carcinoma	12 (18.7%)	4 (13.3%)
Fuhrman grade			0.419	0.518
Ⅰ-Ⅱ	27 (42.9%)	15 (50.0%)
Ⅲ-Ⅳ	36 (57.1%)	15 (50.0%)
Surgical approach			9.601	0.002
Laparoscopic surgery	19 (29.7%)	19 (63.3%)
Open surgery	45 (70.3%)	11 (36.7%)
IVC resection			13.464	<0.001
No	42 (65.6%)	30 (100.0%)
Yes	22 (34.4%)	0 (0)
Operative time/min	362.5 (305.3, 429.8)	307.5 (254.5, 374.0)	644.0	0.010
Surgical bleeding volume/mL	1 200 (325, 2 500)	450 (200, 800)	621.0	0.006
Surgical blood transfusion volume/mL	800 (0, 1 600)	0 (0, 600)	689.0	0.021
Plasma transfusion volume/mL	200 (0, 750)	0 (0, 0)	598.0	0.001
Post-operative hospital stay/d	9.5 (7.0, 13.0)	8.0 (6.0, 9.3)	702.5	0.036
Post-operative adjuvant targeted therapy			2.546	0.111
No	23 (35.9%)	16 (53.3%)
Yes	41 (64.1%)	14 (46.7%)
Post-operative complications			9.417	0.002
No	34 (53.1%)	25 (86.2%)
Yes	30 (46.9%)	4 (13.8%)

表1

表2

图2

表3

参考文献 14

[1]	Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 [J]. Eur J Cancer, 2018, 103:356-387. doi: S0959-8049(18)30955-9 pmid: 30100160
[2]	Lardas M, Stewart F, Scrimgeour D, et al. Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus [J]. Eur Urol, 2016, 70(2):265-280. doi: 10.1016/j.eururo.2015.11.034
[3]	Quencer KB, Friedman T, Sheth R, et al. Tumor thrombus: incidence, imaging, prognosis and treatment [J]. Cardiovasc Diagn Ther, 2017, 7(Suppl 3):S165-S177. doi: 10.21037/cdt
[4]	González J, Gorin MA, Garcia-Roig M, et al. Inferior vena cava resection and reconstruction: Technical considerations in the surgical management of renal cell carcinoma with tumor thrombus [J]. Urol Oncol, 2014, 32(1): 34.e19-26. doi: 10.1016/j.urolonc.2013.01.004
[5]	Adams LC, Ralla B, Bender YY, et al. Renal cell carcinoma with venous extension: prediction of inferior vena cava wall invasion by MRI [J]. Cancer Imaging, 2018, 18(1):17. doi: 10.1186/s40644-018-0150-z pmid: 29724245
[6]	Psutka SP, Boorjian SA, Thompson RH, et al. Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumour thrombus [J]. BJU Int, 2015, 116(3):388-396. doi: 10.1111/bju.13005 pmid: 25430786
[7]	Liu Z, Li L, Hong P, et al. A predictive model for tumor invasion of the inferior vena cava wall using multimodal imaging in patients with renal cell carcinoma and inferior vena cava tumor thrombus [J]. Biomed Res Int, 2020, 2020:9530618.
[8]	Li QY, Li N, Huang QB, et al. Contrast-enhanced ultrasound in detecting wall invasion and differentiating bland from tumor thrombus during robot-assisted inferior vena cava thrombectomy for renal cell carcinoma [J]. Cancer Imaging, 2019, 19(1):79. doi: 10.1186/s40644-019-0265-x
[9]	Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: A population-based study [J]. Lancet Oncol, 2013, 14(2):141-148. doi: 10.1016/S1470-2045(12)70559-4
[10]	Xiao R, Xu C, He W, et al. Preoperative anaemia and thrombocytosis predict adverse prognosis in non-metastatic renal cell carcinoma with tumour thrombus [J]. BMC Urol, 2021, 21(1):31. doi: 10.1186/s12894-021-00796-6
[11]	Du S, Huang Q, Yu H, et al. Initial series of robotic segmental inferior vena cava resection in left renal cell carcinoma with caval tumor thrombus [J]. Urology, 2020, 142:125-132. doi: 10.1016/j.urology.2020.03.053
[12]	Gu L, Li H, Wang Z, et al. A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy [J]. Cancer Treat Rev, 2018, 69:112-120. doi: 10.1016/j.ctrv.2018.06.014
[13]	Rodriguez Faba O, Linares E, Tilki D, et al. Impact of microscopic wall invasion of the renal vein or inferior vena cava on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus: A multi-institutional analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium [J]. Eur Urol Focus, 2018, 4(3):435-441. doi: S2405-4569(17)30018-4 pmid: 28753848
[14]	Wang H, Li X, Huang Q, et al. Prognostic role of bland thrombus in patients treated with resection of renal cell carcinoma with infe-rior vena cava tumor thrombus [J]. Urol Oncol, 2021, 39(5): 302.e1-e7. doi: 10.1016/j.urolonc.2021.02.005

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Items	DITT (n=40)	NITT (n=15)	U/χ²	P value
Operative time/min	368.5 (306.5, 525.0)	302.0 (258.0, 355.0)	139	0.002
Surgical bleeding volume/mL	1 450 (525, 2 925)	400 (200, 800)	152.5	0.005
Surgical blood transfusion volume/mL	800 (0, 1 600)	0 (0, 400)	202	0.054
Plasma transfusion volume/mL	400 (0, 800)	0 (0, 0)	155	0.003
Post-operative hospital stay/d	11.0 (7.0, 13.0)	8.0 (6.0, 9.0)	190	0.036
Open surgery	30 (75.0%)	4 (26.7%)	10.8	0.001
Post-operative complications	22 (55.0%)	2 (13.3%)	7.7	0.006

Items	HR	95%CI	P value
DITT	4.635	1.017-21.116	0.047
Mayo classification	2.046	1.161-3.604	0.013
Hb	-	-	0.484
Non-clear cell carcinoma	4.275	1.495-12.229	0.007
Fuhrman grade (Ⅲ-Ⅳ vs. Ⅰ-Ⅱ)	-	-	0.719

[1]	蓝璘,贺洋,安金刚,张益. 颧骨缺损不同修复重建方法和预后的回顾性分析[J]. 北京大学学报（医学版）, 2022, 54(2): 356-362.
[2]	王飞,朱翔,贺蓓,朱红,沈宁. 自发缓解的滤泡性细支气管炎伴非特异性间质性肺炎1例报道并文献复习[J]. 北京大学学报（医学版）, 2021, 53(6): 1196-1200.
[3]	高伟波,石茂静,张海燕,吴春波,朱继红. 显著高铁蛋白血症与噬血细胞性淋巴组织细胞增多症的相互关系[J]. 北京大学学报（医学版）, 2021, 53(5): 921-927.
[4]	张梅香,史文芝,刘建新,王春键,李燕,王蔚,江滨. MLL-AF6融合基因阳性急性髓系白血病的临床特征及预后[J]. 北京大学学报（医学版）, 2021, 53(5): 915-920.
[5]	田雨,程晓悦,贺慧颖,王国良,马潞林. 肾细胞癌合并尿路瘤栓的临床病理特征: 6例报道及文献回顾[J]. 北京大学学报（医学版）, 2021, 53(5): 928-932.
[6]	蒋艳芳,王健,王永健,刘佳,裴殷,刘晓鹏,敖英芳,马勇. 前交叉韧带翻修重建术后中长期临床疗效及影响因素[J]. 北京大学学报（医学版）, 2021, 53(5): 857-863.
[7]	肖若陶,刘承,徐楚潇,何为,马潞林. 术前血小板参数与局部进展期肾细胞癌预后[J]. 北京大学学报（医学版）, 2021, 53(4): 647-652.
[8]	于妍斐,何世明,吴宇财,熊盛炜,沈棋,李妍妍,杨风,何群,李学松. 延胡索酸水合酶缺陷型肾细胞癌的临床病理特征及预后[J]. 北京大学学报（医学版）, 2021, 53(4): 640-646.
[9]	孙争辉,黄晓娟,董靖晗,刘茁,颜野,刘承,马潞林. 临床T1期肾细胞癌肾窦侵犯的危险因素[J]. 北京大学学报（医学版）, 2021, 53(4): 659-664.
[10]	韩松辰,黄子雄,刘慧鑫,徐涛. 单侧肾细胞癌根治性切除术后的肾功能代偿[J]. 北京大学学报（医学版）, 2021, 53(4): 680-685.
[11]	陈怀安,刘硕,李秀君,王哲,张潮,李凤岐,苗文隆. 炎症生物标志物对输尿管尿路上皮癌患者预后预测的临床价值[J]. 北京大学学报（医学版）, 2021, 53(2): 302-307.
[12]	刘世博,高辉,冯元春,李静,张彤,万利,刘燕鹰,李胜光,罗成华,张学武. 腹膜后纤维化致肾盂积水的临床分析:附17例报道[J]. 北京大学学报（医学版）, 2020, 52(6): 1069-1074.
[13]	陈伟钱,戴小娜,余叶,王沁,梁钧昱,柯旖旎,易彩虹,林进. 原发性干燥综合征合并自身免疫性肝病的临床特点及预后分析[J]. 北京大学学报（医学版）, 2020, 52(5): 886-891.
[14]	毕海,黄毅,马潞林,陆敏,张树栋,张洪宪. 3例肾尤文肉瘤合并下腔静脉癌栓的诊治[J]. 北京大学学报（医学版）, 2020, 52(5): 985-989.
[15]	姜妮,乔国梁,王小利,周心娜,周蕾,宋雨光,赵艳杰,任军. 中性粒细胞与淋巴细胞比例对评估接受过继性细胞免疫治疗的晚期胰腺癌患者预后的临床意义[J]. 北京大学学报（医学版）, 2020, 52(3): 597-602.